Arcellx, Inc. (ACLX)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
Loading interactive chart…
- GuruFocus.com
Arcellx Inc (ACLX) Q1 2024 Earnings: Narrower Losses and Revenue Surge
Financial Outcomes Show Significant Improvement, Beating Revenue Estimates
- Zacks
Arcellx, Inc. (ACLX) Reports Q1 Loss, Tops Revenue Estimates
Arcellx (ACLX) delivered earnings and revenue surprises of 72.55% and 32.55%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
REDWOOD CITY, Calif. & SANTA MONICA, Calif., May 09, 2024--Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX) today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma program. Anito-cel is the first BCMA CAR T to be investigated in multiple myeloma that utilizes Arcellx’s novel and compact D-Domain binder.
© 2024 Yahoo. All rights reserved.